IDWeek 2023: Showcasing the Critical Role of mRNA in Tackling Infectious Disease
Today kicks off IDWeek 2023, one of the leading infectious disease events in the world, and Moderna is looking forward to engaging with the infectious disease community from around the globe. This annual meeting presents a unique opportunity to collaborate with experts and highlight the incredible work being done to advance the field of infectious disease prevention– an area where we are rapidly innovating.
Moderna’s Presence at IDWeek 2023
In recent months, Moderna has gained great momentum within its infectious disease portfolio. This includes the recent approval of our updated COVID-19 vaccine, Spikevax, in many countries, positive results from a Phase 3 trial of our flu vaccine, the completion of our U.S. regulatory filing for our adult respiratory syncytial virus (RSV) vaccine, and the completed enrollment of our phase 3 trial for a first-in-class vaccine against cytomegalovirus (CMV). At IDWeek 2023, Moderna will be presenting 15 posters that highlight our latest research in these areas and more. In addition to the 15 posters, Moderna will also deliver two late-breaking oral presentations, including:
Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
(Friday, October 13ᵗʰ, 2:45 – 2:57pm ET):
Dean Follmann, PhD, Chief of the Biostatistics Research Branch at the National Institute of Allergy and Infectious Diseases, will present research that assessed the impact of age and the length of the dosing interval on the efficacy of a booster dose of Moderna’s COVID-19 vaccine (mRNA-1273) during the Delta and Omicron variant waves.
Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial
(Saturday, October 14ᵗʰ, 2:25-2:35pm ET): Sandeep Basnet, MD, Director of Clinical Development at Moderna, will present data from Moderna’s phase 2 trial of its CMV vaccine.
Moderna will host two Learning Lounges to foster fruitful discussion on the future of COVID-19 vaccination, including:
Navigating the New Normal: Vaccinating Against COVID-19 in 2023 and Beyond
(Thursday, October 12ᵗʰ, 11:15am – 12:00pm ET, Learning Lounge 2): Join Stuart H. Cohen, MD, Medical Director of Hospital Epidemiology, Division Chief, Infectious Disease, University of California, Davis, as he discusses the enduring impact of COVID-19 on public health and how vaccination can help address the evolving needs for protection against COVID-19, especially in higher-risk populations.
The Role of Infectious Disease Specialists in Supporting Community Vaccination (Saturday, October 14ᵗʰ, 12:15 – 1:00pm ET, Learning Lounge 2): Join for a discussion on the importance of establishing infectious disease specialists as vaccinology experts within communities, exploring the scientific and behavioral challenges providers face with patients when recommending COVID-19 vaccination. Speakers include:
Angela Branche, MD, Associate Professor of Medicine, University of Rochester Medical Center
William Fischer, PhD, Distinguished Professor Emeritus and Adjunct Research Professor in Social and Personality Psychology, University of Western Ontario
Buddy Creech, MD, MPH, Edie Carell Johnson Chair and Professor of Pediatrics, Division of Pediatric Infectious Diseases, Vanderbilt University of Medicine (moderator)
A Deeper Look at the Impact of COVID-19 Vaccination in the Immunocompromised
At the event Moderna will distribute a supplement published in The Journal of Infectious Disease, which features eight papers that examine COVID-19’s impact on the immunocompromised population. This includes discussion of the ongoing burden of the virus, as well as data surrounding the response to COVID-19 vaccination according to the immunosuppressive condition, including recipients of organ transplants, those with cancer, and other conditions.
Immunocompromised individuals may require different COVID-19 vaccination approaches than others due to their varied immune responses. By further characterizing the immune response in different patient groups, these findings could ultimately help identify those who may benefit from alternative vaccination strategies, and inform clearly articulated, individualized recommendations to help improve uptake among this population.
Visit Us at IDWeek 2023
If you’re planning to attend IDWeek 2023, we invite you to stop by our booth #2208 to learn more about our recent research and participate in an immersive virtual reality experience into the world of mRNA manufacturing, which will take visitors through the pre-clinical lab spaces at Moderna’s manufacturing facility in Norwood, MA.
Click here to register for IDWeek 2023 and learn more about Moderna’s presence.